|    |                                          |
|----|------------------------------------------|
| I. | Contribution and Exchange of Securities. |

----

|     |                                 |
|-----|---------------------------------|
| II. | Conditions to Rollover Closing. |

|      |                                                                                                                                                                                                                                          |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| III. | Representations and Warranties of Parent and HHHH.  Each of Parent and HHHH, solely as to itself, represents and warrants to the Holders as of the date hereof and as of the Rollover Closing (except as otherwise provided) as follows: |

----

|     |                                                                                                                                                                                                                              |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IV. | Representations and Warranties of Each Holder.  Each Holder, solely as to itself, represents and warrants to Parent and HHHH as of the date hereof and as of the Rollover Closing (except as otherwise provided) as follows: |

----

|    |                           |
|----|---------------------------|
| V. | Restrictions on Transfer. |

|     |                      |
|-----|----------------------|
| VI. | Certain Tax Matters. |

----

|      |                |
|------|----------------|
| VII. | Miscellaneous. |

----

----

----

----

----

----

----

----

|    |                                                                     |
|----|---------------------------------------------------------------------|
| 1) | State and federal income tax expense for the Relevant Period, plus; |

|    |                                                              |
|----|--------------------------------------------------------------|
| 2) | Depreciation and amortization for the Relevant Period, plus; |

|    |                                                                                                                                        |
|----|----------------------------------------------------------------------------------------------------------------------------------------|
| 3) | Accrued interest expense on the HealthSouth Note and any other indebtedness of HHHH or its subsidiaries for the Relevant Period, plus; |

|    |                                                                                    |
|----|------------------------------------------------------------------------------------|
| 4) | Accrued incentive equity compensation/SARs/expenses for the Relevant Period, plus; |

|    |                                            |
|----|--------------------------------------------|
| 5) | Gain/loss on disposal of any assets, plus; |

|    |                                                                                                             |
|----|-------------------------------------------------------------------------------------------------------------|
| 6) | Any extraordinary charges or losses determined in accordance with generally accepted accounting principles. |

----

|         |                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Market Multiple Definition:  Median of the FV/LTM EBITDA multiples (adjusted for acquisitions) for the “Public Home Health Trading Comparable List” and the “Home Health Transaction Comparable List.” |

|         |                                                                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | “Public Home Health Trading Comparable List”:  Includes HealthSouth, Kindred, Amedisys, LHC Group and Almost Family.  List can be revised due to new public home health companies or delisting from the public markets. |

|         |                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | “Home Health Transaction Comparable List”:  Includes any home health transactions in the past twelve months on a rolling basis that meet the following criteria: |

|    |                                      |
|----|--------------------------------------|
| 1) | Greater than 60% home health revenue |

|    |                                            |
|----|--------------------------------------------|
| 2) | Transaction size greater than $400 million |

|    |                                                   |
|----|---------------------------------------------------|
| 3) | Excludes any HealthSouth home health acquisitions |

----

|                                                |
|------------------------------------------------|
|                                                |  |
| % of Performance SARsmeeting achievement       | Actual 2017 EBITDA(in millions) |
| 0%                                             | less than $107.325 |
| 95%                                            | $107.325 |
| 100%105%                                       | $112.973$118.622 and above |
| and ratably between such actual EBITDA amounts |

----

|                                                                     |
|---------------------------------------------------------------------|
|                                                                     |  |
| % of Restricted Stock grants meeting achievement                    | % of Applicable Target EBITDA for year of grant |
| 0%                                                                  | less than 95% |
| 60%                                                                 | 95% |
| 80%100%                                                             | 100%105% and above |
| and ratably in between such percentages of applicable Target EBITDA |

----